Scientists peek inside tumors to see how new drug fights HER2 cancers
NCT ID NCT04294628
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This early-phase study looks at how the drug DS-8201a affects tumor cells and the immune system in people with advanced HER2-positive cancers that have stopped responding to standard treatments. Researchers will take small tumor samples before and after treatment to measure changes in proteins and immune cells. The goal is to learn how the drug works, not to test a cure or long-term control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.